Upcoming IPO: Gemphire Therapeutics
Wednesday, July 6, 2016
Posted by: Kate Oesterle
Biopharmaceutical company Gemphire Therapeutics (NASDAQ: GEMP) is slated to price its IPO this week, according to published reports.
Northville, Michigan-based Gemphire was co-founded by former Pfizer employees Dr. Charles Bisgaier and David Lowenschuss who licensed the rights to Pfizer's gemcabene molecule in April 2011.
Subsequently, the company hired Mina Sooch as CEO, and has been progressing its lead drug candidate gemcabene through phase 1 and phase 2 clinical trials.
Read full article.